Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

October 01, 1996; Volume 279,Issue 1

Articles

  • You have access
    ERRATUM
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 442;
  • You have access
    ERRATUM
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 442;
  • You have access
    Effects of gonadal steroids on vascular function.
    S P Duckles, D N Krause and V M Miller
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 1-3;
  • You have access
    In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians.
    R B Kim, H Yamazaki, K Chiba, D O'Shea, M Mimura, F P Guengerich, T Ishizaki, T Shimada and G R Wilkinson
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 4-11;
  • You have access
    Evaluation of sex- and strain-dependency of cocaine-induced immunosuppression in B6C3F1 and DBA/2 mice.
    R A Matulka, S D Jordan, E D Stanulis and M P Holsapple
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 12-17;
  • You have access
    Melatonin modulation of presynaptic nicotinic acetylcholine receptors in the rat vas deferens.
    R P Markus, W M Zago and R C Carneiro
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 18-22;
  • You have access
    Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
    G Zernig, T Burke, J W Lewis and J H Woods
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 23-31;
  • You have access
    Dilazep and its derivative, K-7259, attenuate mechanical derangement induced by palmitoyl-L-carnitine in the isolated, perfused rat heart.
    A Hara, H Hashizume and Y Abiko
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 32-38;
  • You have access
    Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    L F Tseng and K A Collins
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 39-46;
  • You have access
    Restoration of ischemic contractile failure of indo-1-loaded guinea pig heart by a calcium sensitizer, MCI-154.
    Y Abe, K Sekioka, R Ishisu, K Onishi, Y Ueda and T Nakano
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 47-55;
  • You have access
    Binding of the volatile anesthetic halothane to the hydrophobic core of a tetra-alpha-helix-bundle protein.
    J S Johansson, F Rabanal and P L Dutton
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 56-61;
  • You have access
    [3H]MDL 105,519, a high-affinity radioligand for the N-methyl-D-aspartate receptor-associated glycine recognition site.
    B M Baron, B W Siegel, B L Harrison, R S Gross, C Hawes and P Towers
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 62-68;
  • You have access
    Inhalation exposure to volatilized opioids produces antinociception in mice.
    A H Lichtman, Y Meng and B R Martin
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 69-76;
  • You have access
    Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
    D Wu and W M Pardridge
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 77-83;
  • You have access
    Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines.
    D Debernardis, S Stanzione, C Ottoboni, L Clerico, T Mancuso, S Parodi and P Russo
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 84-90;
  • You have access
    Nitric oxide generation by renal proximal tubules: role of nitric oxide in the cytotoxicity of lipid A.
    L A Traylor, J W Proksch, V C Beanum and P R Mayeux
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 91-96;
  • You have access
    Effects of a phorbol ester and isoquinoline sulfonamides on rabbit parietal cell function.
    J Nandi, M C Bosche and R A Levine
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 97-105;
  • You have access
    Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain.
    T Kobayashi, K Matsuno, K Nakata and S Mita
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 106-113;
  • You have access
    The inhibitory effect of angiotensin II on stimulus-induced release of cAMP is augmented in the genetically hypertensive rat kidney.
    S J Vyas, Z Mi and E K Jackson
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 114-119;
  • You have access
    Effects of levosimendan on myocardial contractility and oxygen consumption.
    K Todaka, J Wang, G H Yi, R Stennett, M Knecht, M Packer and D Burkhoff
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 120-127;
  • You have access
    Gangliosides reduce the development of ethanol dependence without affecting ethanol tolerance.
    L D Snell, G Szabó, B Tabakoff and P L Hoffman
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 128-136;
  • You have access
    Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching.
    D F Woodward, A L Nieves and M H Friedlaender
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 137-142;
  • You have access
    Glycine and calcium-dependent effects of lead on N-methyl-D-aspartate receptor function in rat hippocampal neurons.
    M Marchioro, K L Swanson, Y Aracava and E X Albuquerque
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 143-153;
  • You have access
    Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors.
    D R Lynch and M J Gallagher
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 154-161;
  • You have access
    Pharmacological advantages of conjugation of Cu, Zn-superoxide dismutase with succinylated keratin fragment: improvement of biological properties and resistance to oxidative damage.
    J Noda, M Otagiri, T Akaike and H Maeda
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 162-171;
  • You have access
    Changes in opioid receptor density on murine splenocytes induced by in vivo treatment with morphine and methadone.
    G Patrini, P Massi, G Ricevuti, A Mazzone, G Fossati, I Mazzucchelli, E Gori and D Parolaro
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 172-176;
  • You have access
    Effect of the highly selective and nonpeptide delta opioid receptor agonist TAN-67 on the morphine-induced place preference in mice.
    T Suzuki, M Tsuji, T Mori, M Misawa, T Endoh and H Nagase
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 177-185;
  • You have access
    Effects of the androgenic/anabolic steroid stanozolol on GABAA receptor function: GABA-stimulated 36Cl- influx and [35S] TBPS binding.
    A E Masonis and M P McCarthy
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 186-193;
  • You have access
    Carnitine and choline derivatives containing a trimethylamine group prevent ammonia toxicity in mice and glutamate toxicity in primary cultures of neurons.
    M D Miñana, C Hermenegildo, M Llsansola, C Montoliu, S Grisolía and V Felipo
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 194-199;
  • You have access
    Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 [3 beta-(3p-chlorophenyl) tropan-2 beta-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride].
    A E Fleckenstein, S Pögün, F I Carroll and M J Kuhar
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 200-206;
  • You have access
    Platelet-activating factor (PAF) stimulates giant migrating contractions during ileal inflammation.
    P Jouët and S K Sarna
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 207-213;
  • You have access
    Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay.
    S Wilson, J K Chambers, J E Park, A Ladurner, D W Cronk, C G Chapman, H Kallender, M J Browne, G J Murphy and P W Young
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 214-221;
  • You have access
    Species differences in the disposition and metabolism of nalidixic acid.
    A A Nomeir, P Markham, L T Burka, R J Griffin and B I Ghanayem
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 222-230;
  • You have access
    Rhythm anomalies related to delayed repolarization in vivo: influence of sarcolemmal Ca++ entry and intracellular Ca++ overload.
    L Carlsson, L Drews and G Duker
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 231-239;
  • You have access
    Interleukin-5 production by peripheral blood mononuclear cells of asthmatic patients is suppressed by T-440: relation to phosphodiesterase inhibition.
    O Kaminuma, A Mori, M Suko, H Kikkawa, K Ikezawa and H Okudaira
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 240-246;
  • You have access
    Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors.
    M R Bergman and B J Holycross
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 247-254;
  • You have access
    Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet.
    L Grélot, H Le Stunff, S Milano, P R Blower and D Romain
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 255-261;
  • You have access
    Characterization of the prostanoid TP receptor population in human nonpregnant myometrium.
    M Senchyna and D J Crankshaw
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 262-270;
  • You have access
    Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine.
    C Ito, K Onodera, E Sakurai, M Sato and T Watanabe
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 271-276;
  • You have access
    Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo.
    S E Gartside, R McQuade and T Sharp
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 277-283;
  • You have access
    Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake.
    K Sawai, R I Mahato, Y Oka, Y Takakura and M Hashida
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 284-290;
  • You have access
    The systemic and cerebral kinetics of thiopental in sheep: enantiomeric analysis.
    L E Mather, R N Upton, J L Huang, G L Ludbrook, E Gray and C Grant
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 291-297;
  • You have access
    Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
    M Sato, H U Bryant, P Iversen, J Helterbrand, F Smietana, K Bemis, R Higgs, C H Turner, I Owan, Y Takano and D B Burr
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 298-305;
  • You have access
    Mechanisms of action of cholecystokinin in the canine gastrointestinal tract: role of vasoactive intestinal peptide and nitric oxide.
    P Vergara, Z Woskowska, S Cipris, J E Fox-Threlkeld and E E Daniel
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 306-316;
  • You have access
    Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion.
    B E Heisler and G R Ferrier
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 317-324;
  • You have access
    Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography.
    B T Christian, E Livni, J W Babich, N M Alpert, D D Dischino, E Ruediger, D E Salazar, N F Ford and A J Fischman
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 325-331;
  • You have access
    Hypothermia and metabolic stress: narrowing the cellular site of early neuroprotection.
    G D Zeevalk and W J Nicklas
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 332-339;
  • You have access
    Soluble cytokine receptors as carrier proteins: effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4.
    Y Ma, H E Hurst and R Fernandez-Botran
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 340-350;
  • You have access
    Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"-pattern cocaine administration and chronic withdrawal.
    Y Zhou, R Spangler, K S LaForge, C E Maggos, A Ho and M J Kreek
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 351-358;
  • You have access
    Cocaine-induced peroxidative stress in rat liver: antioxidant enzymes and mitochondria.
    B G Devi and A W Chan
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 359-366;
  • You have access
    Stable expression and characterization of recombinant human heteromeric N-methyl-D-aspartate receptor subtypes NMDAR1A/2A and NMDAR1A/2B in mammalian cells.
    M A Varney, C Jachec, C Deal, S D Hess, L P Daggett, R Skvoretz, M Urcan, J H Morrison, T Moran, E C Johnson and G Veliçelebi
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 367-378;
  • You have access
    Neural stimulation of Egr-1 messenger RNA expression in rat adrenal gland: possible relation to phenylethanolamine N-methyltransferase gene regulation.
    K Morita, R A Bell, B J Siddall and D L Wong
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 379-385;
  • You have access
    Ontogeny and hormonal basis of female-dominant rat hepatic sulfotransferases.
    L Liu and C D Klaassen
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 386-391;
  • You have access
    Differential effects of intra-accumbens sulpiride on cocaine-induced locomotion and conditioned place preference.
    D A Baker, T V Khroyan, L E O'Dell, R A Fuchs and J L Neisewander
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 392-401;
  • You have access
    Inhibitory mechanism of CO2 inhalation on slowly adapting pulmonary stretch receptors in the anesthetized rabbit.
    S Matsumoto, H Okamura, K Suzuki, N Sugai and T Shimizu
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 402-409;
  • You have access
    Glutamate ameliorates experimental vincristine neuropathy.
    F M Boyle, H R Wheeler and G M Shenfield
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 410-415;
  • You have access
    In vitro inactivation of human O6-alkylguanine DNA alkyltransferase by antitumor triazene compounds.
    P M Lacal, S D'Atri, L Orlando, E Bonmassar and G Graziani
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 416-422;
  • You have access
    Radioligand binding, autoradiographic and functional studies demonstrate tachykinin NK-2 receptors in dog urinary bladder.
    C J Mussap, C Stamatakos and E Burcher
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 423-434;
  • You have access
    Lead (Pb+2) promotes apoptosis in newborn rat cerebellar neurons: pathological implications.
    A Oberto, N Marks, H L Evans and A Guidotti
    Journal of Pharmacology and Experimental Therapeutics October 1996, 279 (1) 435-442;
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 279, Issue 1
1 Oct 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Articles
  • Most Cited
  • Most Read
Loading
  • Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
  • Functional Selectivity and Classical Concepts of Quantitative Pharmacology
  • Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
  • The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data
  • A METHOD FOR DETERMINING LOSS OF PAIN SENSATION
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics